Document Detail


Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind, placebo-controlled trial.
MedLine Citation:
PMID:  3358568     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
STUDY OBJECTIVE: To determine the efficacy and toxicity of intralesionally administered interferons in the treatment of condyloma acuminatum. DESIGN: Randomized, double-blind, and placebo-controlled study. SETTING: Outpatient clinics at university medical centers. PATIENTS: Seventy-nine patients with biopsy-proved condyloma acuminatum that was refractory to conventional therapy were enrolled in the study. INTERVENTIONS: Alpha-2b, alpha-nl-, and beta-interferons were used. One wart on each patients was injected three times per week for 4 weeks with either 1 x 10(6) units of interferon or placebo. MEASUREMENTS AND MAIN RESULTS: Forty-seven percent of warts injected with interferon resolved completely, compared with 22% of placebo-injected warts (P = 0.009). In addition, more recipients of interferon had a complete resolution of uninjected lesions. No differences in rates of response were noted among the different interferon groups. Approximately one third of interferon-injected warts recurred, compared with none of four placebo-injected warts. Intralesionally administered interferon was nontoxic and well tolerated, although transient pain on injection was observed frequently. CONCLUSIONS: Intralesional administration of each of these three interferons appears to be useful in treating condyloma acuminatum. However, the frequent recurrence of disease and the failure of many lesions to resolve indicate that different regimens, such as longer courses of therapy or different routes of administration, should be evaluated to maximize beneficial effects of interferon for treating this common sexually transmitted disease.
Authors:
R C Reichman; D Oakes; W Bonnez; C Greisberger; S Tyring; L Miller; R Whitley; H Carveth; M Weidner; G Krueger
Related Documents :
19259418 - An analysis of risk factors for developing hepatocellular carcinoma in a group of hepat...
16764068 - Therapeutic options for treatment experienced patients: a focus on resistance testing a...
12360468 - Adherence to combination therapy enhances sustained response in genotype-1-infected pat...
9106118 - Long-term, high dose interferon-alpha treatment in htlv-i-associated myelopathy/tropica...
7742278 - Phototherapeutic keratectomy for bullous keratopathy.
21485418 - Economic model for emergency use authorization of intravenous peramivir.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Annals of internal medicine     Volume:  108     ISSN:  0003-4819     ISO Abbreviation:  Ann. Intern. Med.     Publication Date:  1988 May 
Date Detail:
Created Date:  1988-05-16     Completed Date:  1988-05-16     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0372351     Medline TA:  Ann Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  675-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, University of Rochester School of Medicine and Dentistry, New York.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anus Neoplasms / therapy
Condylomata Acuminata / pathology,  therapy*
Double-Blind Method
Female
Genital Neoplasms, Female / therapy
Genital Neoplasms, Male / therapy
Humans
Injections
Interferon Type I / administration & dosage*,  adverse effects,  blood
Male
Neoplasm Recurrence, Local
Random Allocation
Grant Support
ID/Acronym/Agency:
N01-AI-32510/AI/NIAID NIH HHS; RR032/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Interferon Type I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The clinical effectiveness of pneumococcal vaccine in the elderly.
Next Document:  Liver disease associated with occupational exposure to the solvent dimethylformamide.